Cartesian Therapeutics to Participate in Upcoming Investor Conferences

FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

• A fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET on Thursday, September 10, 2026
• One-on-one and group investor meetings at Morgan Stanley’s 24th Annual Healthcare Conference on Monday, September 14, 2026
• A fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference at 1:30 p.m. ET on Tuesday, September 15, 2026
  
  

Live webcasts of the fireside chats are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Investor Contact

Megan LeDuc
Associate Director, Investor Relations
[email protected]

Media Contact

David Rosen
Argot Partners
[email protected]

Source: Cartesian Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• New Fluke Engineering Lab at Washington State University Opens to Prepare the Next Generation of Engineers
• Form 8.3 - DCC plc
• OCI N.V. Statement Regarding Petition Filed by Value8